Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals is a Canada‐based specialty pharmaceutical company dedicated to the development, licensing and commercialization of innovative therapies for serious and niche disease areas. The company focuses on leveraging in‐licensing agreements and strategic acquisitions to build a diversified portfolio that addresses unmet needs in hematology, immunology and other rare conditions.

The company’s commercial portfolio includes Syfovre (sutimlimab-jome), an FDA‐approved therapy for cold agglutinin disease that marks Medexus’s first U.S. hematology launch. In addition to its marketed products, Medexus maintains a pipeline of clinical candidates targeting disorders in hematologic, neurologic and immunologic indications. These programs are advanced through partnerships and collaboration agreements designed to accelerate development and broaden patient access.

Headquartered in Montreal, Medexus conducts operations across Canada and the United States, utilizing a lean organizational model supported by a direct U.S. sales force and regional distribution partners. This approach allows the company to efficiently bring new therapies to market while maintaining flexibility in resource allocation and market strategy.

Medexus is led by a management team with extensive experience in specialty pharmaceuticals, biotechnology and commercial execution. The leadership’s combined expertise in drug development, regulatory affairs and business development underpins the company’s efforts to expand its product offerings and deliver therapeutic solutions to patients with high‐unmet medical needs.

Key Stats

• Today's Range: $2.05 to $2.07
• 50-Day Range: $1.85 to $2.48
• 52-Week Range: $1.27 to $3.88
• Volume: 5,600 shs
• Average Volume: 22,603 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

MEDXF Stock Analysis - Frequently Asked Questions

How have MEDXF shares performed this year?

Medexus Pharmaceuticals' stock was trading at $2.4150 at the start of the year. Since then, MEDXF stock has decreased by 15.0% and is now trading at $2.0520.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MEDXF
• CIK: N/A
• Web: www.medexus.com
• Phone: (514) 344-8765
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A